Cancer is more than a set of mutations. At TRiCBiO, we use patient-derived tumor organoids and high-throughput functional genomics to discover real, actionable targets for next-generation therapies.
We maintain a living biobank of over 1,500+ patient-derived tumor organoids, spanning common and rare cancers. Our models retain genetic stability and microenvironmental fidelity, enabling clinically relevant screening and modeling.
